All Oncology News

Consistent DFS benefit was observed with adjuvant nivolumab vs placebo in all patients with muscle-invasive bladder cancer enrolled in CheckMate-274.

Enfortumab vedotin significantly improved outcomes for patients with unresectable or metastatic urothelial carcinoma, according to real-world data.

Favorable responses were demonstrated with the treatment of axatilimab plus ruxolitinib/belumosudil in heavily pretreated patients with chronic GVHD.

Responses were similar among patients with estrogen patches and ARPIs compared to aLHRH and ARPIs in metastatic prostate cancer.

Fox Chase Cancer Center announced the hiring of Michael Noonan, DO, MS, as an Assistant Professor in the Supportive Oncology and Palliative Care Program.

P-BCMA-ALLO1 displayed early efficacy and safety data in relapsed/refractory multiple myeloma.

Zamto-cel produced responses and was associated with low rates of CD19 and/or CD20 antigen loss in relapsed/refractory diffuse large B-cell lymphoma.

Nivolumab plus relatlimab did not improve recurrence-free survival vs nivolumab in resected stage III/IV melanoma.

See this full list of regulatory decisions from 2024 regarding withdrawn agents, label updates, and new drug formulations.

First-line therapy with olaparib plus abiraterone demonstrated clinical benefit in rPFS and OS in mCRPC harboring germline and somatic BRCA mutations.

The addition of darolutamide to ADT improved rPFS and other efficacy end points vs placebo plus ADT in mHSPC.

Treatment of EBRT with or without STAD for 6 months demonstrated an improvement in prostate cancer-specific survival in intermediate-risk prostate cancer.

A low composite gene expression score was associated with improved outcomes in patients with mCRPC who received bavdegalutamide.

G-CSF use and docetaxel dose modifications allowed patients with mHSPC to receive efficacious doses of docetaxel in the ARASENS trial.

Adding Lu-PSMA-617 to enzalutamide significantly improved overall survival and quality of life in metastatic castration-resistant prostate cancer.

Anakinra did not reduce cytokine release syndrome or immune effector cell–associated neurotoxicity in patients with large B-cell lymphoma receiving liso-cel.

Multidisciplinary treatment addresses all facets of patient health, resulting in personalized prostate cancer treatment plans that optimize outcomes.

NKTR-255 combined with CD19-directed CAR T-cell therapy improved 6-month CR rates vs placebo in patients with relapsed/refractory large B-cell lymphoma.

OPN-6602, a small molecule EP300/CBP inhibitor, received orphan drug designation for multiple myeloma.

A high-risk CAR-HEMATOTOX score was associated with worse outcomes with obe-cel in relapsed/refractory B-ALL.

The UK Medicines and Healthcare Products Regulatory Agency has approved the kit for the preparation of gallium-68 gozetotide injection.

Talazoparib plus enzalutamide demonstrates improved overall survival in metastatic castration-resistant prostate cancer.

The designation underscores the potential of the CAR T-cell therapy NXC-201 to serve as a new option in relapsed/refractory AL amyloidosis.

Experts provide insights on the 2024 FDA approvals in several different fields including solid tumors and more in this list featuring the regulatory decisions.

Experts highlight the top presentations to watch for at the 2025 Genitourinary Cancers Symposium.

Daniel J. DeAngelo, MD, PhD, details how the split dosing of obe-cel yields reduced toxicities and makes it a unique CAR T-cell therapy for relapsed/refractory ALL.

Ritu Salani, MD, MBA, details considerations for cervical cancer treatment as new approvals, research, and modalities affect several settings.

Short-course, higher dose vaginal brachytherapy for endometrial cancer had similar effectiveness to more frequent, lower dose sessions.

The NCCN guidelines have been updated to specify the standing of ctDNA as a biomarker in colon and rectal cancer, as well as in MCC.

CUSP06 received fast track designation from the FDA for patients with platinum-resistant ovarian cancer.